CONNECT WITH US
HealthTech

HealthTech

Mortality, comorbidity risk increased with generalized pustular psoriasis

Medical Xpress logo

Published on

Add as a preferred source on Google
Mortality, comorbidity risk increased with generalized pustular psoriasis

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Generalized pustular psoriasis (GPP) is associated with higher mortality and comorbidity risks than psoriasis vulgaris (PV), according to a study published online Sept. 2 in Frontiers in Immunology. The risks also were higher than those among nonpsoriatic controls.

Teng-Li Lin, M.D., from Dalin Tzu Chi Hospital in Chiayi, Taiwan, and colleagues compared mortality and major comorbidities among individuals with GPP, those with PV and nonpsoriatic individuals. Patients with GPP were matched by propensity score to those with PV and nonpsoriatic controls by age, sex and race in a 1:1 ratio. Among patients with GPP, separate matching was performed for those receiving biologics, conventional antipsoriatic drugs or small-molecule inhibitors versus those receiving systemic corticosteroids alone.

Overall, 6,959 GPP-PV pairs and 28,459 GPP-nonpsoriatic pairs were analyzed after matching. The researchers found that patients with GPP had higher five-year mortality than those with PV and nonpsoriatic controls (hazard ratios, 1.83 and 2.42, respectively).

94, respectively). Compared with nonpsoriatic controls, they had elevated risks across all evaluated comorbidities. Mortality risks were particularly pronounced among patients older than 60 and men. 71), while conventional antipsoriatic drugs and small-molecule inhibitors were not.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.